Stryker Stock News

Major players in healthcare are increasing their commitments to return capital to shareholders, resulting in significantly higher dividends. Recent dividend announcements from major companies in the sector highlight evolving capital return strategies.

Portage, Michigan, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable January 30, 2026, to shareholders of record at the close of business on December 31, 2025, representing an increase of 4.8% versus the prior year and previous quarter.  “We remain confident in our ability to deliver strong fin...

Portage, Michighan, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today Spencer Stiles has been appointed President and Chief Operating Officer (COO), effective January 1, 2026. In this role, Stiles will lead the company's global businesses, strategy, and mergers and acquisitions.

Over $500 million in insider stock sales have hit three high-profile companies this month—an unsettling signal that even top executives and major stakeholders may be questioning the sustainability of recent gains.

Stryker Corporation ( SYK ) Analyst/Investor Day November 13, 2025 2:30 PM EST Company Participants Jason Beach - Vice President of Finance & Investor Relations Kevin Lobo - Chairman, CEO & President Spencer Stiles - Group President of Orthopaedics Dylan Crotty - President of Instruments Kathy Truppi J. Pierce - Group President of MedSurg & Neurotechnology Tim Lanier Viju Menon - Group Presiden...

Aging populations and wage inflation are making automation economically compelling across warehouses, factories, hospitals, and service industries. The robotics market encompasses a range of industries and niches, from mature surgical systems to warehouse automation and even humanoid platforms designed for household chores.

Stryker (SYK) delivered strong Q3 2025 results, raising full-year guidance on robust organic growth across both MedSurg & Neurotechnology and Orthopaedics segments. SYK achieved double-digit organic sales and EPS growth, supported by margin expansion and successful product launches. Despite operational strength, SYK trades at a significant valuation premium to sector peers, with a PEG ratio abo...

Stryker continues to deliver strong organic growth, having posted organic growth rates of around 10% for a long period of time now. The $4.9 billion Inari Medical acquisition announced this year will boost the neurovascular business and slightly increase leverage, but deleveraging attempts are quite impressive. Valuation multiples have compressed to 26x earnings, making SYK more appealing as ea...